Role of Immune Tolerance Induction Public Workshop
The Food and Drug Administration's (FDA) Center for Drug Evaluation and Research, in co-sponsorship with the National Organization for Rare Disorders (NORD), is announcing a one-day public workshop entitled “Immune Responses to Enzyme Replacement Therapies: Role of Immune Tolerance Induction.” Partners and stakeholders planning the workshop also include representatives from academia, industry and patients. The purpose of this workshop is to provide a forum to discuss the role of immune tolerance induction in patients receiving replacement biological products.
The workshop will be available via webcast at: https://collaboration.fda.gov/immuneresponse/.
FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)
FDA White Oak Campus, Building 31, the Great Room
White Oak Conference Center, Silver Spring, Maryland
Rekha Abichandani, MD, Assessing immunogenicity during clinical development: – An Industry Perspective
Laurence A. Turka, Pharmacologic Approaches for Immune Tolerance
Jeanine R Utz, PharmD BCOP BCPS, Non-Cytotoxic, Non-Immunosuppressing Approach to Tolerance Induction During ERT Treatment